Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma

Authors

Mary E. Westerman, University of Texas MD Anderson Cancer Center
Daniel D. Shapiro, University of Texas MD Anderson Cancer Center
Christopher G. Wood, University of Texas MD Anderson Cancer Center
Jose A. Karam, University of Texas MD Anderson Cancer Center

Document Type

Article

Publication Date

8-1-2020

Publication Title

The Urologic clinics of North America

Abstract

There has been strong interest in using neoadjuvant therapy to decrease recurrence rates and facilitate surgical resection in locally advanced renal cell carcinoma. To date, no evidence exists to support improvement in oncologic outcomes with neoadjuvant therapy. Likewise, although targeted therapies have shown efficacy in tumor downsizing, this does not often translate to downstaging. Use of presurgical therapy for the purpose of downstaging inferior vena cava tumor thrombi is currently not supported. Future studies evaluating the benefit of newer immune checkpoint inhibitors will determine if there is a larger role for neoadjuvant therapy in locally advanced renal cell carcinoma.

First Page

329

Last Page

343

DOI

10.1016/j.ucl.2020.04.010

Recommended Citation

Westerman, Mary E.; Shapiro, Daniel D.; Wood, Christopher G.; and Karam, Jose A., "Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma" (2020). LSU-LCMC Cancer Center Faculty Publications. 21.
https://digitalscholar.lsuhsc.edu/llcc_facpubs/21
10.1016/j.ucl.2020.04.010